Loading...
Coverage, strength, recency, conviction and momentum.
No analyses found yet.
Newest calls at the top.
Jenny Harrington evaluates Sabra Healthcare as her top pick for 2026, highlighting its attractive valuation at 12x FFO and a dividend yield exceeding 6%. The speaker analyzes the positive demographic trends favoring senior housing and skilled nursing facilities, examining the stock's upside potential relative to the broader market run-up.
The speaker analyzes this healthcare REIT as a top pick for 2026, citing favorable demographic trends in senior housing and skilled nursing. The review notes the attractive valuation at half the market multiple, a high dividend yield, and the view that AI serves as a benefit rather than a threat to the business model.
Jenny Harrington evaluates the positive factors for Sabra Health Care, including its 6.3% dividend yield, lack of AI threat, and demographic tailwinds.
Jenny Harrington evaluates Sabra Healthcare as her top pick for 2026, highlighting its attractive valuation at 12x FFO and a dividend yield exceeding 6%. The speaker analyzes the positive demographic trends favoring senior housing and skilled nursing facilities, examining the stock's upside potential relative to the broader market run-up.
The speaker analyzes this healthcare REIT as a top pick for 2026, citing favorable demographic trends in senior housing and skilled nursing. The review notes the attractive valuation at half the market multiple, a high dividend yield, and the view that AI serves as a benefit rather than a threat to the business model.
Jenny Harrington evaluates the positive factors for Sabra Health Care, including its 6.3% dividend yield, lack of AI threat, and demographic tailwinds.